Valuation: Stoke Therapeutics, Inc.

Market Cap 1.73B 1.57B 1.45B 1.31B 2.47B 161B 2.56B 17.45B 6.9B 87.09B 6.48B 6.34B 275B P/E 2026 *
-6.64x
P/E 2027 * -6.43x
Enterprise Value 1.54B 1.4B 1.29B 1.16B 2.2B 144B 2.28B 15.55B 6.15B 77.56B 5.77B 5.65B 245B EV / Sales 2026 *
44.3x
EV / Sales 2027 * 31.8x
Free-Float
95.98%
Yield 2026 *
-
Yield 2027 * -
1 day-0.83%
1 week-2.94%
Current month+0.46%
1 month+9.27%
3 months-17.80%
6 months-12.20%
Current year-16.79%
1 week 25.65
Extreme 25.65
27.7
1 month 24.13
Extreme 24.13
28.44
Current year 22.05
Extreme 22.05
40.22
1 year 22.05
Extreme 22.05
40.22
3 years 3.77
Extreme 3.77
40.22
5 years 3.35
Extreme 3.35
40.22
10 years 3.35
Extreme 3.35
71.58
Manager TitleAgeSince
Chief Executive Officer 60 19/03/2025
Chief Tech/Sci/R&D Officer 54 01/06/2014
Director of Finance/CFO 49 07/05/2024
Director TitleAgeSince
Chairman 65 01/07/2015
Director/Board Member 67 01/06/2014
Director/Board Member 72 01/09/2015
Date Insider Type Main position Quantity % Market Cap. Importance
02/11/26 Sell

Chief Technology Officer

-7,195 0.0112%
02/10/26 Sell

General Counsel

-627 0.0011%
01/10/26 Sell

Chief Technology Officer

-1,051 0.0018%
Change 5-day change 1-year change 3-year change Capi.($)
-0.83%-2.94%-2.00%+525.83% 1.73B
+1.15%-2.81%+55.79%+71.12% 66.37B
-2.64%-1.13%+7.82%+88.90% 58.86B
-1.07%+0.30%+22.91%+86.76% 55.22B
+0.48%-2.53%+9.73%+121.14% 47.21B
-2.69%-6.38%+19.19%+25.79% 42.45B
-0.70%+4.93%+17.77%+45.03% 36.44B
-2.50%-15.73%+135.31%+662.73% 35.19B
-0.77%-2.21%+77.27%+57.96% 32.66B
-0.83%+1.98%-38.27%+390.98% 26.73B
Average -1.04%-2.45%+30.55%+207.62% 40B
Weighted average by Cap. -0.97%-2.19%+33.78%+148.37%

Financials

2026 *2027 *
Net sales 34.72M 31.52M 29.11M 26.27M 49.59M 3.24B 51.48M 351M 139M 1.75B 130M 128M 5.53B 47.07M 42.73M 39.48M 35.61M 67.23M 4.4B 69.8M 476M 188M 2.37B 177M 173M 7.5B
Net income -264M -240M -221M -200M -377M -24.68B -392M -2.67B -1.06B -13.32B -991M -970M -42.07B -298M -270M -250M -225M -425M -27.82B -442M -3.01B -1.19B -15.01B -1.12B -1.09B -47.44B
Net Debt -189M -172M -158M -143M -270M -17.66B -280M -1.91B -755M -9.53B -709M -694M -30.11B -228M -207M -191M -173M -326M -21.33B -339M -2.31B -913M -11.51B -857M -839M -36.37B
Projected Income Statement - Annual - Stoke Therapeutics, Inc.
Logo Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Employees
170
Date Price Change Volume
17/11/26 $26.41 -0.83% 556,996
16/11/26 $26.63 -0.19% 581,599
13/11/26 $26.68 +1.83% 420,232
12/11/26 $26.20 -5.62% 501,225
11/11/26 $27.76 +2.02% 836,813
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Stoke Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
26.41USD
Average target price
46.38USD
Spread / Average Target
+75.63%
  1. Stock Market
  2. Stocks
  3. STOK Stock